MOLECULAR MECHANISMS REGULATING SRD5A2 EXPRESSION IN BENIGN PROSTATIC HYPERPLASIA

Resume. Benign prostatic hyperplasia (BPH) is among the most prevalent urological disorders affecting aging men and represents a significant clinical concern due to its progressive nature and its impact on quality of life. Currently, the primary therapeutic approaches used for the management of BPH include watchful waiting, pharmacological treatment, and surgical intervention. The selection of treatment strategy generally depends on symptom severity, prostate volume, disease progression, and patient-related factors. Among these therapeutic approaches, pharmacological management remains the most commonly applied first-line treatment in patients presenting with lower urinary tract symptoms (LUTS).Drug therapy for BPH primarily involves the use of alpha-adrenergic receptor blockers and 5-alpha reductase inhibitors (5-ARIs). Alpha-blockers improve urinary symptoms through relaxation of smooth muscle fibers within the prostate and bladder neck, thereby reducing urinary obstruction and improving urine flow. In contrast, 5-alpha reductase inhibitors directly target the hormonal mechanisms involved in prostate growth and enlargement. Keywords: SRD5A2, alpha-adrenergic blockers, prostate gland, inhibitor, 5-alpha reductase, benign prostatic hyperplasia.

Hali tarjima qilinmagan